Background: A total of 10682 patients were admitted in our tertiary care COVID hospital from April 2020 to January 2021. 419 patients died with a mortality rate of 3.92%. We have analysed 241 deaths that have taken place till 10 th September 2020. Methodology: We studied the history, symptomatology, HRCT chest, comorbidities, duration of hospital stay and special drugs administered along with the type of oxygen therapy. Results: 88% of patients have more than 30% lung burden by HRCT. All the patients have a CO-RADS score of 4 or more. 81% of the patients have CT severity index of 15/25 or more. The CO-RADS classification is a standardized reporting system for patients with suspected COVID-19 infection developed for a moderate to high prevalence setting. 71% of patients expired within first five days of admission. 23% of patients died in 5 to 10 days of admission. 80% of patients presenting with < 80% SPO 2 died in first five days. 77% of patients have single or multiple comorbidities. 23% of patients did not have any comorbidities. 34% of patients gave history of alcohol intake 41.9% have history of smoking. 38% of patients gave past history of lung disease. Shortness of breath, generalized weakness and cough were the common symptoms. Loss of smell was seen in 22% and loss of taste was seen in 25%. 81% of patients had more than 5 days of symptoms before admission. 19% had less than 5 days of symptoms. 73% of patients presented with Modified Medical research Council Scale Grade 3 or 4 breathlessness. Patients required oxygen in multiple forms. Only 5% of patients were put on mechanical ventilator. Remdesivir was given in 96% of patients. Anti IL6 Tocilizumab was given in 25%. Plasma therapy was given in 5%. Conclusions: Patients dying of COVID-19 disease had significant CT scan changes suggestive of corona disease. Past history of lung disease was seen in only a third. Shortness of breath was the commonest symptom and majority of the patients presented with SPO 2 of <90% and moderate to severe breathlessness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.